385 new fatalities have been recorded and the toll has mounted to 1,40,958. The recovery rate remains high and the total discharged cases stand at 91,78,946 with 39,045 new discharges in the last 24 hours.
ALSO READ| Bharat Biotech Applies For Emergency Authorization Of 'Covaxin', Becomes Second Indian Company To Seek Approval
Vaccine plans for India
During an all-party meet on Friday Prime Minister Narendra Modi has said that nearly eight vaccines are at different stages of trial with their manufacturing assured in India and once the scientists give a green signal it will be released in a few weeks. In the last few days, significant developments have taken place as several pharma companies have applied for approval for emergency use of coronavirus vaccine in India.
US-based drugmaker Pfizer Inc. and the world's largest vaccine maker by volume, the Serum Institute of India (SII) have applied for emergency use authorization of the vaccine in India and expects the vaccine rollout before March 2021. In its application submitted to the drug regulator on December 4, Pfizer has sought permission to import the vaccine for sale and distribution in the country, besides waiver of clinical trials on the Indian population under the New Drugs' special provisions and Clinical Trials Rules, 2019.
SII had also sought emergency use authorization in the country for AstraZeneca Plc's Covid-19 vaccine.
Hyderabad based pharmaceutical Bharat Biotech has also applied for emergency authorization for its COVID-19 vaccine “Covaxin”, became the second Indian vaccine candidate that applied to the Central Drugs Standard Control Organization (CDSCO).